Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Surbone

Showing results (41-50 of 52) with videos related to

Pageof 6
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 1993
Paclitaxel and recombinant human granulocyte colony-stimulating factor as initial chemotherapy for metastatic breast cancerB S Reichman, A D Seidman, J P Crown, et al.
Annals of the New York Academy of Sciences|November 30, 1993
Taxol and recombinant human granulocyte colony-stimulating factor, an active regimen as initial therapy for metastatic breast cancer. A preliminary reportB S Reichman, A D Seidman, J P Crown, et al.
Seminars in Oncology|August 1, 1993
Preliminary experience with paclitaxel (Taxol) plus recombinant human granulocyte colony-stimulating factor in the treatment of breast cancerA D Seidman, L Norton, B S Reichman, et al.
Journal of the National Cancer Institute. Monographs|January 1, 1993
Taxol plus recombinant human granulocyte-colony stimulating factor as initial and as salvage chemotherapy for metastatic breast cancer: a preliminary reportA D Seidman, B S Reichman, J P Crown, et al.
Oncology|October 1, 1994
Taxol (paclitaxel) plus recombinant human granulocyte colony-stimulating factor in the treatment of metastatic breast cancerA D Seidman, L Norton, B S Reichman, et al.
Psychosomatic Medicine|November 1, 1992
An experimental analysis of classically conditioned nausea during cancer chemotherapyD H Bovbjerg, W H Redd, P B Jacobsen, et al.
Cancer Investigation|March 26, 1998
Lack of increased cardiac toxicity with sequential doxorubicin and paclitaxelC Hudis, L Riccio, A Seidman, et al.
Seminars in Oncology|February 1, 1996
Sequential adjuvant therapy: the Memorial Sloan-Kettering Cancer Center experienceC Hudis, A Seidman, G Raptis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 24, 1999
Sequential dose-dense doxorubicin, paclitaxel, and cyclophosphamide for resectable high-risk breast cancer: feasibility and efficacyC Hudis, A Seidman, J Baselga, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 26, 1999
Phase I study of escalating doses of edatrexate in combination with paclitaxel in patients with metastatic breast cancerG D'Andrea, D Fennelly, L Norton, et al.
Pageof 6

Showing results (41-50 of 52) with videos related to

Sort By:
Pageof 6
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 1993
Paclitaxel and recombinant human granulocyte colony-stimulating factor as initial chemotherapy for metastatic breast cancerB S Reichman, A D Seidman, J P Crown, et al.
Annals of the New York Academy of Sciences|November 30, 1993
Taxol and recombinant human granulocyte colony-stimulating factor, an active regimen as initial therapy for metastatic breast cancer. A preliminary reportB S Reichman, A D Seidman, J P Crown, et al.
Seminars in Oncology|August 1, 1993
Preliminary experience with paclitaxel (Taxol) plus recombinant human granulocyte colony-stimulating factor in the treatment of breast cancerA D Seidman, L Norton, B S Reichman, et al.
Journal of the National Cancer Institute. Monographs|January 1, 1993
Taxol plus recombinant human granulocyte-colony stimulating factor as initial and as salvage chemotherapy for metastatic breast cancer: a preliminary reportA D Seidman, B S Reichman, J P Crown, et al.
Oncology|October 1, 1994
Taxol (paclitaxel) plus recombinant human granulocyte colony-stimulating factor in the treatment of metastatic breast cancerA D Seidman, L Norton, B S Reichman, et al.
Psychosomatic Medicine|November 1, 1992
An experimental analysis of classically conditioned nausea during cancer chemotherapyD H Bovbjerg, W H Redd, P B Jacobsen, et al.
Cancer Investigation|March 26, 1998
Lack of increased cardiac toxicity with sequential doxorubicin and paclitaxelC Hudis, L Riccio, A Seidman, et al.
Seminars in Oncology|February 1, 1996
Sequential adjuvant therapy: the Memorial Sloan-Kettering Cancer Center experienceC Hudis, A Seidman, G Raptis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 24, 1999
Sequential dose-dense doxorubicin, paclitaxel, and cyclophosphamide for resectable high-risk breast cancer: feasibility and efficacyC Hudis, A Seidman, J Baselga, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 26, 1999
Phase I study of escalating doses of edatrexate in combination with paclitaxel in patients with metastatic breast cancerG D'Andrea, D Fennelly, L Norton, et al.
Pageof 6